This trial will evaluate the use of immunotherapy and PARP inhibition in a population with
incurable advanced breast cancer associated with a germline BRCA mutation or HDR-defect. The
main objective is to examine overall response rate of pembrolizumab (immunotherapy) in
combination with Olaparib (PARP inhibitor) in advanced BRCA-mutated or Homology-directed
repair (HDR)-defect breast cancer.